ENTITY
Shanghai Henlius Biotech

Shanghai Henlius Biotech (2696 HK)

317
Analysis
Health Care • China
Shanghai Henlius Biotech, Inc develops and produces drugs. The Company develops and produces monoclonal antibody biosimilar drugs, bio betters, novel monoclonal antibodys, and other drugs. Shanghai Henlius Biotech throughout China.
more
•01 Sep 2024 07:00

Last Week in Event SPACE: Shin Kong/Taishin Financial, Jardine Matheson, Toyota Motors, Huafa Props

The weekend is here! Pour yourself a coffee, grab a comfortable seat, and sift through a brief summary of insights on various events discussed...

Logo
565 Views
Share
bullish•Seven & I Holdings
•31 Aug 2024 15:00

(Mostly) Asia-Pac M&A: Seven & I, Silverlake Axis, Shanghai Henlius, CPMC, Shinko Electric, Arvida

This insight provides a summary of gross/annualised spreads (on deals discussed on Smartkarma) across Asia-Pacific as at the last trading date, and...

Logo
612 Views
Share
•26 Aug 2024 09:29

Henlius (2696 HK): Was There Any Doubt?

The scrip option is here. Currently trading at a gross/annualised spread of 7.4%/16.2%, assuming mid-February payment. I'd get involved  here. I'd...

Logo
653 Views
Share
•26 Aug 2024 08:55

Shanghai Henlius Biotech (2696.HK) - Privatization Has Taken a Positive Step Forward

Share Alternative is necessary to improve success rate of privatization, but there're risk behind. As  undervaluation of Henlius is difficult to...

Logo
776 Views
Share
•26 Aug 2024 00:27

Merger Arb Mondays (26 Aug) - China TCM, Henlius, Canvest, GA Pack, Huafa, Tohokushinsha

This week, the highest gross spreads are HEC Pharma (109.7%), China TCM (12.7%), Canvest (11.9%), Malaysia Airports (7.8%), Capitol (7.4%), Henlius...

Logo
471 Views
Share
x